PA8572601A1 - Compuestos de 3,4-dihidroquinolin-2 (1h)-ona como antagonistas del receptor nr2b - Google Patents
Compuestos de 3,4-dihidroquinolin-2 (1h)-ona como antagonistas del receptor nr2bInfo
- Publication number
- PA8572601A1 PA8572601A1 PA20038572601A PA8572601A PA8572601A1 PA 8572601 A1 PA8572601 A1 PA 8572601A1 PA 20038572601 A PA20038572601 A PA 20038572601A PA 8572601 A PA8572601 A PA 8572601A PA 8572601 A1 PA8572601 A1 PA 8572601A1
- Authority
- PA
- Panama
- Prior art keywords
- compound
- dihydroquinolin
- receptor antagonists
- compounds
- rent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA PRESENTE INVENCION PROVEE UN COMPUESTO DE LA FORMULA (I) EN LA QUE R1 ES FLUORO, CLORO, BROMO, ALQUILO C1-3 o ALCOXI C1-3; Y R2 ES HIDROGENO, FLUORO, CLORO, BROMO, ALQUILO C1-3 o ALCOX C1-3; O UN ESTER FARMACEUTICAMENTE ACEPTABLE DE DICHO COMPUESTO. O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO. ESTOS COMPUESTOS RESULTAN UTILES PARA EL TRATAMIENTO DE ENFERMEDADES CAUSADAS POR SOBREACTIVACION DEL RECEPTOR NR2B DEL NMDA, TALES COMO EL DOLOR, EL ACCIDENTE CEREBROVASCULAR, LA LESION CEREBRAL TRAUMATICA, LA ENFERMEDAD DE PARKINSON, LA ENFERMEDAD DE ALZHEIMER, LA DEPRESION, LA ANSIEDAD, LA MIGRAÑA O SIMILARES EN UN MAMIFERO, EN ESPECIAL, EN LOS SERES HUMANOS. ESTA INVENCION TAMBIEN PROVEE UNA COMPOSICION FARMACEUTICA QUE COMPRENDE EL COMPUESTO ANTERIOR.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37593902P | 2002-04-26 | 2002-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PA8572601A1 true PA8572601A1 (es) | 2004-12-16 |
Family
ID=29270728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA20038572601A PA8572601A1 (es) | 2002-04-26 | 2003-04-25 | Compuestos de 3,4-dihidroquinolin-2 (1h)-ona como antagonistas del receptor nr2b |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6713490B2 (es) |
| EP (1) | EP1499606B8 (es) |
| JP (1) | JP2005524696A (es) |
| AR (1) | AR039663A1 (es) |
| AT (1) | ATE325117T1 (es) |
| AU (1) | AU2003219398A1 (es) |
| BR (1) | BR0309778A (es) |
| CA (1) | CA2483636A1 (es) |
| DE (1) | DE60305026T2 (es) |
| ES (1) | ES2258716T3 (es) |
| MX (1) | MXPA04010549A (es) |
| PA (1) | PA8572601A1 (es) |
| TW (1) | TW200406402A (es) |
| UY (1) | UY27776A1 (es) |
| WO (1) | WO2003091241A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69722426T3 (de) | 1996-07-24 | 2015-05-07 | Warner-Lambert Company LLC (n.Ges. des Staates Delaware) | Isobutylgaba und dessen derivate zur schmerzbehandlung |
| MXPA06003748A (es) * | 2003-10-08 | 2006-06-14 | Pfizer | Compuestos de lactama condensada. |
| ES2246687B2 (es) * | 2004-02-11 | 2006-11-16 | Miguel Muñoz Saez | Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales. |
| JPWO2005097782A1 (ja) * | 2004-04-07 | 2007-08-16 | 協和醗酵工業株式会社 | ピペリジン誘導体 |
| HU226977B1 (en) * | 2004-07-29 | 2010-04-28 | Richter Gedeon Nyrt | Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them |
| WO2008027557A2 (en) * | 2006-08-31 | 2008-03-06 | Spherics, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
| US8008253B2 (en) * | 2007-07-03 | 2011-08-30 | Andrew Tasker | Treatment for anxiety |
| EP2116618A1 (en) | 2008-05-09 | 2009-11-11 | Agency for Science, Technology And Research | Diagnosis and treatment of Kawasaki disease |
| WO2010036937A1 (en) | 2008-09-27 | 2010-04-01 | Taraxos Inc. | Topical formulations for treatment of neuropathy |
| EP2437740B1 (en) * | 2009-03-31 | 2015-04-29 | Tinnitus Research Initiative (TRI) | Treatment of tinnitus and associated auditory dysfunctions |
| WO2011145062A1 (en) | 2010-05-21 | 2011-11-24 | Link Research & Grants Corporation | Treatment of tinnitus and related auditory dysfunctions |
| EP2621475A1 (en) | 2010-10-02 | 2013-08-07 | Link Research&Grants Corporation | Treatment of tinnitus and related auditory dysfunctions |
| WO2013156614A1 (en) | 2012-04-20 | 2013-10-24 | Ucb Pharma S.A. | Methods for treating parkinson's disease |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4902695A (en) | 1989-02-13 | 1990-02-20 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| ES2146578T3 (es) | 1990-05-10 | 2000-08-16 | Pfizer | Indolona neuroprotectora y derivados relacionados. |
| BR9307331A (pt) | 1992-10-30 | 1999-05-25 | Pfizer | Compostos neuroprotetores 3,4-dihidro-2(1ho-quinolona |
| PA8525601A1 (es) | 2000-08-21 | 2002-04-25 | Hoffmann La Roche | Profarmacos de (3s,4s)-4-bencil-1-[2-(4-hidroxi-bencenosulfonil)-etil]-piperidin-3-ol |
-
2003
- 2003-04-14 US US10/413,029 patent/US6713490B2/en not_active Expired - Fee Related
- 2003-04-15 BR BR0309778-1A patent/BR0309778A/pt not_active IP Right Cessation
- 2003-04-15 DE DE60305026T patent/DE60305026T2/de not_active Expired - Fee Related
- 2003-04-15 AT AT03715209T patent/ATE325117T1/de not_active IP Right Cessation
- 2003-04-15 EP EP03715209A patent/EP1499606B8/en not_active Expired - Lifetime
- 2003-04-15 JP JP2003587800A patent/JP2005524696A/ja not_active Withdrawn
- 2003-04-15 CA CA002483636A patent/CA2483636A1/en not_active Abandoned
- 2003-04-15 WO PCT/IB2003/001556 patent/WO2003091241A1/en active IP Right Grant
- 2003-04-15 ES ES03715209T patent/ES2258716T3/es not_active Expired - Lifetime
- 2003-04-15 MX MXPA04010549A patent/MXPA04010549A/es not_active Application Discontinuation
- 2003-04-15 AU AU2003219398A patent/AU2003219398A1/en not_active Abandoned
- 2003-04-24 AR ARP030101424A patent/AR039663A1/es unknown
- 2003-04-24 UY UY27776A patent/UY27776A1/es not_active Application Discontinuation
- 2003-04-25 TW TW092109786A patent/TW200406402A/zh unknown
- 2003-04-25 PA PA20038572601A patent/PA8572601A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20030216430A1 (en) | 2003-11-20 |
| MXPA04010549A (es) | 2005-02-17 |
| ATE325117T1 (de) | 2006-06-15 |
| WO2003091241A1 (en) | 2003-11-06 |
| BR0309778A (pt) | 2005-03-08 |
| DE60305026T2 (de) | 2006-10-12 |
| EP1499606A1 (en) | 2005-01-26 |
| ES2258716T3 (es) | 2006-09-01 |
| UY27776A1 (es) | 2003-11-28 |
| EP1499606B1 (en) | 2006-05-03 |
| AR039663A1 (es) | 2005-03-02 |
| TW200406402A (en) | 2004-05-01 |
| US6713490B2 (en) | 2004-03-30 |
| CA2483636A1 (en) | 2003-11-06 |
| EP1499606B8 (en) | 2006-08-30 |
| JP2005524696A (ja) | 2005-08-18 |
| DE60305026D1 (de) | 2006-06-08 |
| AU2003219398A1 (en) | 2003-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8572601A1 (es) | Compuestos de 3,4-dihidroquinolin-2 (1h)-ona como antagonistas del receptor nr2b | |
| CO6361928A2 (es) | Modulares de aril metil benzoquinazolinona alostericos positivos del receptor m1 | |
| PE20240646A1 (es) | Compuestos farmaceuticos | |
| RU2008116931A (ru) | Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей | |
| NI201200107A (es) | Moduladores alostéricos positivos de receptores m1 de la quinolina amida | |
| UY29265A1 (es) | Compuestos de 3h-oxazolo y 3h-tiazolo(4,5,-d)pirimidin-2-ona 3,5- disustituidos y 3,5,7-trisustituidos y sus profármacos | |
| PA8549901A1 (es) | Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales o neuronales | |
| PA8531001A1 (es) | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos | |
| ECSP055719A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
| CO6501188A2 (es) | Moduladores de piranil aril metil benzoquinazolina alostéricos positivos del receptos m1 | |
| CU23112A3 (es) | AMINOáCIDOS BICICLICOS COMO AGENTES FARMACéUTICOS | |
| GT200500098A (es) | Nuevos compuestos | |
| PA8442001A1 (es) | Derivados de pirimidina biciclica condensada | |
| PA8627201A1 (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos | |
| MY145694A (en) | Spiroheterocyclic compounds and their uses as therapeutic agents | |
| SV2006002135A (es) | Nucleosidos de 3-beta-d-ribofuranosiltiazolo [4,5-d] pirimidina y usos de los mismos | |
| JP2005502680A5 (es) | ||
| GT200000203A (es) | Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas. | |
| UY29823A1 (es) | Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones | |
| ECSP088967A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
| CY1113759T1 (el) | Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2 | |
| BR0111140A (pt) | Forma polimórfica, composição farmacêutica, métodos para o tratamento de uma doença inflamatória, de uma doença mediada por ciclooxigenase, de dor, e, processo para fabricar um polimorfo de forma v | |
| ECSP088966A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
| AR014747A1 (es) | Derivados de piperidina, un procedimiento para prepararlos, el empleo de los mismos para preparar un medicamento, una composicion farmaceutica que loscontiene y un procedimiento para obtener esta composicion farmaceutica | |
| JP2011516489A (ja) | 疾患誘発性運動失調症および非運動失調性平衡異常の治療法 |